FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck Sharp & Dohme LLC.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Cutaneous Angiosarcoma
- Sub-indication
- General
Related signal: Pembrolizumab and Lenvatinib Trial for Unresectable Cutaneous Angiosarcoma Initiated